Response to the NCEPOD report: Development of a care bundle for patients admitted with decompensated cirrhosis - The first 24 h

Frontline Gastroenterology

Volumn 7, Issue 1, 2016, Pages 16-23

  McPherson, Stuart ^a,b   Dyson, Jessica ^a,b   Austin, Andrew ^c,d   Hudson, Mark ^a,b,e  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d British Thoracic Society   (United Kingdom)

^e The British Institute of NDT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL SYNDROME; ASCITES; BRAIN DISEASE; CARE BUNDLE; CHECKLIST; DECOMPENSATED LIVER CIRRHOSIS; DELIRIUM; EARLY INTERVENTION; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HOSPITAL ADMISSION; HUMAN; HYPONATREMIA; INFECTION; JAUNDICE; LENGTH OF STAY; LIVER CIRRHOSIS; MEDICAL SPECIALIST; MORTALITY; PRIORITY JOURNAL; REVIEW; SEPSIS; UNITED KINGDOM;

EID: 84961797395     PISSN: 20414137     EISSN: 20414145     Source Type: Journal    
DOI: 10.1136/flgastro-2014-100491     Document Type: Review

References (52)

1. NHS liver care. NHS Atlas of Variation for People with liver disease: reducing the unwanted variation to increase value and improve quality. Right Care 2013: 1-141.
2. Thomson SJ, Westlake S, Rahman TM, et al. Chronic liver disease - an increasing problem: a study of hospital admission and mortality rates in England, 1979-2005, with particular reference to alcoholic liver disease. Alcohol Alcohol 2008; 43: 416-22.
3. A Time to act: Improving Health and Outcomes in Liver Disease. The national plan for liver services (UK) British Society of Gastroenterology; 2009: 1-52.
4. Moreau R, Arroyo V Acute on chronic liver failure: a new clinical entity. Clin Gastroenterol Hepatol Published Online First: 27 Feb 2014.
5. NCEPOD. "Measuring the Units"-a review of patients who died with alcoholic related liver disease. National Confidential Enquiry into Patient Outcome and Death (UK); 2013: 1-25.
6. Physicians RCo. National Early Warning Score (NEWS): standardising the assessment of acute illness in the NHS. 2012: 1-47.
7. Gines P, Fernandez J, Durand F, et al. Management of criticallyill cirrhotic patients. J Hepatol 2012; 56(Suppl. 1): S13-24.
8. Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60: 1310-24.
9. Papp M, Vitalis Z, Altorjay I, et al. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. Liver Int 2012; 32: 603-11.
10. EASL. Clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
11. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006; 55(Suppl. 6): vi1-12.
12. Desborough M, Jairath V, Sekhar M, et al. Multi Regional Audit of Blood Component Use in Patients with Cirrhosis. NHS Blood and Transplant, 2014.
13. NICE Clinical Guideline 100: Alcohol use disorders. National Institute of Health and Clinical Excellence (UK); 2010: 1-15.
14. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353-7.
15. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986; 6: 252-62.
16. Borzio M, Salerno F, Piantoni L, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41-8.
17. Pleguezuelo M, Benitez JM, Jurado J, et al. Diagnosis and management of bacterial infections in decompensated cirrhosis. World J Hepatol 2013; 5: 16-25.
18. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8.
19. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005; 54: 718-25.
20. Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-61.
21. Chinnock B, Afarian H, Minnigan H, et al. Physician clinical impression does not rule out spontaneous bacterial peritonitis in patients undergoing emergency department paracentesis. Ann Emerg Med 2008; 52: 268-73.
22. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32: 142-53.
23. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.
24. Scott RA, Austin AS, Kolhe NV, et al. Acute kidney injury is independently associated with death in patients with cirrhosis. Frontline Gastroenterol 2013; 4: 191-7.
25. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-77.
26. NICE Clinical Guideline 169: Acute Kidney Injury. National Institute of Health and Clinical Excellence (UK); 2013: 1-39.
27. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
28. Angeli P, Sanyal A, Moller S, et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int 2013; 33: 16-23.
29. Gluud LL, Christensen K, Christensen E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-84.
30. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int 2012; 2(Suppl): 1-138.
31. Berry PA, Thomson SJ. The patient presenting with decompensated cirrhosis. Acute Med 2013; 12: 232-8.
32. NICE Clinical Guideline 174: Intravenous fluid therapy in adults in hospital. National Institute for Health and Clinical Excellence (UK); 2013: 1-36.
33. Lewington A, Kanagasundaram S. Clinical Practice Guidelines: Acute Kidney Injury. The Renal Association 2011: 1-55.
34. McCormick PA, Mistry P, Kaye G, et al. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut 1990; 31: 204-7.
35. Jairath V, Rehal S, Logan R, et al. Acute variceal haemorrhage in the United Kingdom: Patient characteristics, management and outcomes in a nationwide audit. Dig Liver Dis 2014; 46: 419-26.
36. Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. Gut 2000; 46(Suppl 3-4): III1-15.
37. de Franchis R, Baveno VF. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-8.
38. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368: 11-21.
39. NICE Clinical guideline 141: Acute upper gastrointestinal bleeding. National Institute of Health and Clinical Excellence (UK); 2012: 1-24.
40. Wells M, Chande N, Adams P, et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 2012; 35: 1267-78.
41. Levacher S, Letoumelin P, Pateron D, et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346: 865-8.
42. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010; (9): CD002907.
43. Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-61.
44. Fernandez J, Ruiz del Arbol L, Gomez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131: 1049-56; quiz 285.
45. Brown MR, Jones G, Nash KL, et al. Antibiotic prophylaxis in variceal hemorrhage: timing, effectiveness and Clostridium difficile rates. World J Gastroenterol 2010; 16: 5317-23.
46. Leise MD, Poterucha JJ, Kamath PS, et al. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc 2014; 89: 241-53.
47. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-56.
48. Gatt A, Riddell A, Calvaruso V, et al. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8: 1994-2000.
49. Villa E, Camma C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-60 e1-4.
50. Campillo B, Richardet JP, Scherman E, et al. Evaluation of nutritional practice in hospitalized cirrhotic patients: results of a prospective study. Nutrition 2003; 19: 515-21.
51. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
52. Cholongitas E, Betrosian A, Senzolo M, et al. Prognostic models in cirrhotics admitted to intensive care units better predict outcome when assessed at 48 h after admission. J Gastroenterol Hepatol 2008; 23(8 Pt 1): 1223-7.